本栏目为您提供冠心病、高血压 、血脂异常、心律失常、瓣膜性心脏病、心肌梗塞、先心病 、肺栓塞、心肌病、心力衰竭、肺动脉高压、外周心血管病、糖尿病、脑卒中、代谢综合征、急性冠脉综合征、心血管综合 相关幻灯课件,您可以免费下载使用
点击显示 收起
文件类型:PPT | 文件大小:160KB | 上传时间:06-02-20
摘要:DIABETES研究Cypher sirolimus-eluting stentPrimary Endpoint:In-stent and late lumen loss at 9 months (determined by QCA) Secondary Endpoints:MACE (cardiac death, MI, TLR) at 30 days, 9, 12, and 24 m...
文件类型:PPT | 文件大小:57KB | 上传时间:06-02-20
摘要:ARMYDA研究Atorvastatin for Reduction of Myocardial Damage During AngioplastyPasceri V, et alCirculation 2004。110:674-8ARMYDA TrialAtorvastatin40 mg/dn=76Primary Endpoint:Occurrence of MI, defined ...
文件类型:PPT | 文件大小:1483KB | 上传时间:06-02-20
摘要:AMIHOT研究Aqueous Oxygen Therapy Improves ST –Segment Resolution in Anterior Myocardial Infarction AMIHOT Phase II Clinical StudyJ。 O’Neill,for the AMIHOT InvestigatorsMain Line HealthTCT 2004Wa...
文件类型:PPT | 文件大小:75KB | 上传时间:06-02-20
摘要:AIMI研究AiMI: AngioJet Rheolytic Thrombectomy In Patients Undergoing Primary Angioplasty for Acute MIInfarct size at 1 month larger and mortality higher in AngioJet groupFinal infarct size at 1 mon...
文件类型:PPT | 文件大小:27KB | 上传时间:06-02-20
摘要:AGENTIII研究Ad5FGF-4 geneAdenoviral intracoronary infusion of human angiogenic fibroblast growth factor-4 (FGF-4)Primary Endpoint:Exercise tolerance test time compared with baseline at 12 weeks, 6 ...
文件类型:PPT | 文件大小:1044KB | 上传时间:06-02-20
摘要:COX-2抑制剂在心血管疾病中的应用Use of AnalgesicsMost commonly used medications in the US by survey data#1: acetaminophen#2: ibuprofen#3: aspirin – 50% of users on for cardiovascular prophylaxisAmo...
文件类型:PPT | 文件大小:4004KB | 上传时间:06-02-20
摘要:GPIIb/IIIa抑制剂在PCI中的应用GP IIb/IIIa Inhibitors in the PCI Setting ObjectivesDiscuss the pivotal role of platelets in the development of ischemic complications after percutaneous coronary inter...
文件类型:PPT | 文件大小:165KB | 上传时间:06-02-20
摘要:ESC2004年会最新公布的硝苯地平GITS治疗冠心病国际临床研究-ACTION研究,简体中文,有备注硝苯地平GITS治疗冠心病的国际临床研究A Coronary disease Trial Investigating Outcome with Nifedipine GITS研究背景发...
文件类型:PPT | 文件大小:72KB | 上传时间:06-02-20
摘要:PROVE-ITTIMI-22,AtoZ,RIO-EUROPE研究ESC 2004: Learning as a journeyValentin Fuster MDDirector, Cardiovascular InstituteMount Sinai Medical CenterNew York, NYChristopher Cannon MDStaff cardiologist...
文件类型:PPT | 文件大小:429KB | 上传时间:06-02-20
摘要:高血压心血管事件的临床研究The Relationship of Systolic and Diastolic Blood Pressure to Cardiovascular Disease Risk: Observational DataPrevalence of Hypertension in the USPercent hypertensive18-29Ba...
文件类型:PPT | 文件大小:1918KB | 上传时间:06-02-20
摘要:1 1 10 Favorstightcontrol Favorslesstightcontrol *n=758(meanachievedbloodpressureof144/82mmHg) 。n=390(meanachievedbloodpressureof154/87mmHg) AdaptedfromUKPDSGroup。009 Lesstight(n=390)meanachieved...
文件类型:PPT | 文件大小:1355KB | 上传时间:06-02-20
摘要:高血压与肾病Epidemiology of Renal Disease in HypertensionRenal Disease in Hypertension EpidemiologyEffects of hypertension on the kidneyInteractions of hypertension and concomitant conditions on th...
文件类型:PPT | 文件大小:259KB | 上传时间:06-02-20
摘要:收缩压、舒张压与心血管风险的关系The Relationship of Systolic and Diastolic Blood Pressure to Cardiovascular Disease Risk: Observational DataPrevalence of Hypertension in the USPercent hypertensive1...
文件类型:PPT | 文件大小:1950KB | 上传时间:06-02-20
摘要:Writing Committee Task Force MembersWriting Committee MembersElliott M。 Anbe, Paul Wayne Armstrong, Eric R。Task Force MembersElliott M。 OrnatoAMI StatsIncidence in the United States*Estimated 9...
文件类型:PPT | 文件大小:60KB | 上传时间:06-02-20
摘要:ATP III: An Evidence-Based ReportEpidemiological evidenceClinical trialsPrestatin trials (meta-analysis): ATP IISmall statin trials (meta-analysis)Large statin trialsATP IIILDL-C: Primary Targetof ...
文件类型:PPT | 文件大小:7429KB | 上传时间:06-02-20
摘要:2Coronary mortality: alarming worldwide forecastsAtherosclerosis: a multifactorial diseaseMain risk factors for coronary heart diseaseGlobal projections for the diabetes epidemic: 1995-2010Atherosc...
文件类型:PPT | 文件大小:73KB | 上传时间:06-02-20
摘要:猝死的危险分层The EP show: Risk stratification for sudden death Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis, INArthur Moss MD Professor of Me...
文件类型:PPT | 文件大小:112KB | 上传时间:06-02-20
摘要:SCD-HeFT研究,PROVE-IT研究和SYNERGY研究ACC 2004: SCD-HeFT, PROVE-IT, and SYNERGY under debateEric J Topol MD Provost and Chief Academic Officer Chairman, Department of Cardiovascular Medicine Clevel...
文件类型:PPT | 文件大小:247KB | 上传时间:06-02-20
摘要:VALIANT研究--缬沙坦将成为急性心肌梗死后的一线用药VALIANT研究的结果和意义心梗后治疗中ACEI和ARB的地位VALIANT研究目的和试验设计VALIANT研究的主要结果VALIANT研究的临床意义内容心梗后治疗中ACEI和ARB的地位...
文件类型:PPT | 文件大小:551KB | 上传时间:06-02-20
摘要:由巨噬细胞产生的脂蛋白磷脂酶A2(Lp-PLA2)的主要作用是:催化OX-LDL产生的各种致炎因子,Lp-PLA2水平升高已经被明确为与CRP同样重要的心血管事件独立危险因子。目前由FDA批准的PLAC检测技术现已经用于临床检测L...
文件类型:PPT | 文件大小:59KB | 上传时间:06-02-20
摘要:胆固醇代谢与双重抑制Cholesterol Metabolism and the Concept of Dual Inhibition David E。
文件类型:PPT | 文件大小:65KB | 上传时间:06-02-20
摘要:VALUE研究和MATCH研究VALUE and MATCH: An era of comparative clinical trialsEric J Topol MD Provost and Chief Academic Officer Chairman, Department of Cardiovascular Medicine Cleveland Clinic Foundat...
文件类型:PPT | 文件大小:115KB | 上传时间:06-02-20
摘要:PROVEIT研究是ACC2004最新公布一项继REVERSAL研究后的重要动脉粥样硬化循证研究。该研究及HPS、PROSPER、ALLHAT-LLT、ASCOT-LLA研究结果的结果,NCEPATPIII指南于2004年7月做出了更新修订。Pravastatin or Atorva...
文件类型:PPT | 文件大小:800KB | 上传时间:06-02-20
摘要:阿司匹林抵抗Introduction to Aspirin Resistance。 Steinhubl, MDAspirin HistoryFirst synthesized in pure form by Felix Hoffman of Friedr。(From the German acetylspirsaure + chemical suffix – in)Aspi...
文件类型:PPT | 文件大小:498KB | 上传时间:06-02-20
摘要:Associate Director, Interventional CardiologyBrigham and Women’s HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MA USAASA Resistance and Clinical OutcomesASA Resistance: Key ...
文件类型:PPT | 文件大小:122KB | 上传时间:06-02-20
摘要:阿司匹林在心血管临床中的应用Aspirin Resistance: Significance, Detection and Clinical Management of This Real PhenomenonWebcastMay 10th, 2004Sponsored byEducational ObjectivesDefine Aspirin Resistan...